Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Total Current Liabilities (2017 - 2025)

Cue Biopharma's Total Current Liabilities history spans 9 years, with the latest figure at $15.5 million for Q3 2025.

  • For Q3 2025, Total Current Liabilities fell 7.54% year-over-year to $15.5 million; the TTM value through Sep 2025 reached $15.5 million, down 7.54%, while the annual FY2024 figure was $13.7 million, 19.86% down from the prior year.
  • Total Current Liabilities for Q3 2025 was $15.5 million at Cue Biopharma, down from $19.3 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $19.3 million in Q2 2025 and bottomed at $8.3 million in Q2 2022.
  • The 5-year median for Total Current Liabilities is $15.5 million (2025), against an average of $14.9 million.
  • The largest annual shift saw Total Current Liabilities plummeted 50.08% in 2022 before it skyrocketed 95.93% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $12.8 million in 2021, then fell by 9.69% to $11.5 million in 2022, then surged by 47.91% to $17.1 million in 2023, then dropped by 19.86% to $13.7 million in 2024, then rose by 13.4% to $15.5 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Total Current Liabilities are $15.5 million (Q3 2025), $19.3 million (Q2 2025), and $15.5 million (Q1 2025).